【摘要】 目的　探讨巨细胞病毒（ＣＭＶ）－ＰＰ６５抗原检测在肾移植术后ＣＭＶ病预防中的应用。方法采用免疫过氧化物酶法检测肾移植受者外周血白细胞ＣＭＶ－ＰＰ６５抗原，术后３个月内每周１次。结果１００例肾移植受者中４２例检出ＣＭＶ－ＰＰ６５抗原阳性，初次检出ＣＭＶ－ＰＰ６５抗原的平均时间为（２３．６±１６．７）ｄ，平均抗原阳性细胞数为（７．８±５．３）个／５ ×１０４白细胞。抗病毒治疗中１８例抗原阳性细胞数进一步升高，平均峰值为（１６．４０±３．１）个。５８例抗原血症阴性的受者仅１例发生ＣＭＶ病。４２例ＣＭＶ－ＰＰ６５抗原血症阳性受者抗病毒治疗后抗原血症均阴转，１例发展为ＣＭＶ病，平均阴转时间为（２４． ６±１１． ３） ｄ，平均疗程为（３４． ２±７．１） ｄ。结论 ＣＭＶ－ＰＰ６５抗原监测可指导肾移植术后ＣＭＶ病的预防性治疗。更多还原

【Abstract】 Objective To investigate the significance of cytomegalovirus(CMV) PP65 antigen detection in antiviral treatment to prevent CMV disease after renal allografts. Methods CMV-PP65 antigen was checked by immunohistochemical methods at weekly intervals during the first 3 months after transplantation. Within 24 hours after the CMV-PP65 antigenemia test became positive, ganciclovir was administered at a dose of 1. 25 - 5 mg·kg - 1· d-1 intravenous drip. Results 42 of 100 recipients (42%) developed CMV antigenemia, and 1 of the other 58 cases (1. 7% ) with negative CMV antigenemia developed CMV disease. CMV antigen in all 42 cases(100%) disappeared after antiviral treatmenl, and 1 of them developed CMV disease. CMV antigenemia became negative on average day 24. 6 ±11. 3, and the average duration of antiviral therapy was(34. 2 ±7. 1 ) days. Conclusion Monitoring of CMV-PP65 antigenemia may be effective to guide the prophylactic antiviral therapy of CMV disease in renal allograft recipients, and CMV-PP65 antigen should be detected weekly within the first 3 months after renal transplantation.更多还原